Linezolid for endocarditis: a case series of 14 patients | Zendy

Carlo Tascini | Zendy; M G Bongiorni | Zendy; Roberta Doria | Zendy; Maria Cristina Polidori | Zendy; Riccardo Iapoce | Zendy; Serena Fondelli | Zendy; Enrico Tagliaferri | Zendy; E. Soldati | Zendy; Antonello Di Paolo | Zendy; Alessandro Leonildi | Zendy; Francesco Menichetti | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Linezolid for endocarditis: a case series of 14 patients

Author(s) -

Carlo Tascini,

M G Bongiorni,

Roberta Doria,

Maria Cristina Polidori,

Riccardo Iapoce,

Serena Fondelli,

Enrico Tagliaferri,

E. Soldati,

Antonello Di Paolo,

Alessandro Leonildi,

Francesco Menichetti

Publication year - 2011

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkq506

Subject(s) - linezolid , endocarditis , medicine , antibiotics , surgery , staphylococcus epidermidis , microbiology and biotechnology , bacteria , vancomycin , staphylococcus aureus , biology , genetics

Response of MRSA and MSSA endocarditis was 2/3 (67%) and 4/5 (80%), respectively. All other cases were cured: one VRE; three MRSE; and two cases of polymicrobial endocarditis. Response of native valve endocarditis was 7/8 (87.5%) and that of prosthetic valve endocarditis was 2/2 (100%). In three out of four patients with PM endocarditis (75%), the removal of the PM combined with antibiotic therapy, linezolid monotherapy in one case, was able to heal the infection. In these three patients, PM culture was still positive for the same S. epidermidis strain as isolated from the blood, probably due to the inactivity of linezolid against slime-producing bacteria. 4 Therefore, for PM endocarditis, linezolid may be an option only if the entire device is removed. Patients were followed up for at least 6 months, and no relapses were recorded.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research